Health Care • Biotechnology: Pharmaceutical Preparations
$111.59 ▲ +14.61
(+15.07%)
MKT CAP: $24.37B • VOL: 11.22M
52W L $90 52W H $213
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$94
MEDIAN
$125
MEAN
$127
HIGH
$152
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE INSM TAPE
INSM // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $135.02 | $128.33 | 2025-02-14 | $101.55 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $140.60 | $131.68 | 2025-02-06 | $104.89 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $127.21 | $122.75 | 2025-01-29 | $107.13 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $113.82 | — | 2025-01-17 | $109.36 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $98.20 | $106.01 | 2025-01-09 | $99.32 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $132.79 | $116.05 | 2024-12-18 | $97.08 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $108.24 | $112.71 | 2024-12-04 | $103.78 | -4.3% | 48% | C |